With upwards of a 41% increase in shares over the past five days and over 20.6% in the past month, Janux Therapeutics (NASDAQ:JANX) has seen its year-to-date gains surge an outstanding 511%.

Targeting metastatic castration-resistant prostate cancer, the rise is driven by positive interim results from a Phase 1a trial of JANX007, experimental immunotherapy. Among 16 highly pre-treated patients, the experiment found notable efficacy; all participants had at least a 50% drop in prostate-specific antigen (PSA) levels after 12 weeks. Especially five individuals attained a 99% decrease and ten patients observed a 90% drop, therefore highlighting the potential of the treatment.

• Warning! GuruFocus has detected 1 Warning Sign with JANX.

Citing its potential to beat accepted therapies like Novartis' Pluvicto and Amgen's Xaluritamig, analysts have forecast peak U.S. sales of JANX007 to reach $3 billion. Furthermore appealing clinically is the therapy's superior safety profile, which targets cancer cells only sparingly damaging healthy tissue. With the ability to transform prostate cancer treatment, the encouraging outcomes place Janux Therapeutics as a growing power in oncology. Investor excitement in JANX007 as a breakthrough treatment in the immuno-oncology scene indicates the rising confidence in it.